Stock Scorecard



Stock Summary for Moderna Inc (MRNA) - $25.60 as of 5/13/2025 9:23:16 AM EST

Total Score

13 out of 30

Safety Score

49 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for MRNA

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for MRNA

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for MRNA

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for MRNA

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for MRNA (49 out of 100)

Stock Price Rating (Max of 10) 7
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 7
Book Value to Price (Max of 10) 6
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for MRNA

CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock - CytomX Therapeutics ( NASDAQ:CTMX ) 5/12/2025 10:50:00 AM
CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - CytomX Therapeutics ( NASDAQ:CTMX ) 5/12/2025 10:15:00 AM
CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate ( CX-2051 ) Candidate in Patients with Advanced Colorectal Cancer ( CRC ) 5/12/2025 10:15:00 AM
CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update 5/12/2025 10:15:00 AM
Ellis Island Honors Society Presents the 2025 Ellis Island Medals of Honor 5/11/2025 1:40:00 AM
New FDA Leadership Could Raise The Bar For Drug Approvals 5/9/2025 5:26:00 PM
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation - Virtus LifeSci Biotech Clinical Trials ETF ( ARCA:BBC ) , Capricor Therapeutics ( NASDAQ:CAPR ) 5/7/2025 1:56:00 PM
Stock Market News for May 7, 2025 5/7/2025 1:26:00 PM
VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations 5/7/2025 11:26:00 AM
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver ( EASL ) Congress 2025 5/7/2025 6:01:00 AM

Financial Details for MRNA

Company Overview

Ticker MRNA
Company Name Moderna Inc
Country USA
Description Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 3/31/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 25.60
Price 4 Years Ago 253.98
Last Day Price Updated 5/13/2025 9:23:16 AM EST
Last Day Volume 12,503,345
Average Daily Volume 10,088,844
52-Week High 170.47
52-Week Low 23.15
Last Price to 52 Week Low 10.58%

Valuation Measures

Trailing PE N/A
Industry PE 71.47
Sector PE 47.92
5-Year Average PE -1.15
Free Cash Flow Ratio 6.10
Industry Free Cash Flow Ratio 17.21
Sector Free Cash Flow Ratio 30.82
Current Ratio Most Recent Quarter 4.22
Total Cash Per Share 4.20
Book Value Per Share Most Recent Quarter 26.01
Price to Book Ratio 0.93
Industry Price to Book Ratio 9.53
Sector Price to Book Ratio 27.83
Price to Sales Ratio Twelve Trailing Months 3.13
Industry Price to Sales Ratio Twelve Trailing Months 47.14
Sector Price to Sales Ratio Twelve Trailing Months 25.47
Analyst Buy Ratings 5
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 386,742,000
Market Capitalization 9,900,595,200
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY -85.10%
Annual Earnings Growth 24.46%
Reported EPS 12 Trailing Months -8.73
Reported EPS Past Year -2.52
Reported EPS Prior Year -9.28
Net Income Twelve Trailing Months -3,357,000,000
Net Income Past Year -3,561,000,000
Net Income Prior Year -4,714,000,000
Quarterly Revenue Growth YOY -35.30%
5-Year Revenue Growth 132.11%
Operating Margin Twelve Trailing Months -972.00%

Balance Sheet

Total Cash Most Recent Quarter 1,623,000,000
Total Cash Past Year 1,927,000,000
Total Cash Prior Year 2,907,000,000
Net Cash Position Most Recent Quarter 1,623,000,000
Net Cash Position Past Year 1,927,000,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 10,901,000,000
Total Stockholder Equity Prior Year 13,854,000,000
Total Stockholder Equity Most Recent Quarter 10,066,000,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -4,024,000,000
Free Cash Flow Per Share Twelve Trailing Months -10.40
Free Cash Flow Past Year -4,055,000,000
Free Cash Flow Prior Year -3,825,000,000

Options

Put/Call Ratio 0.51
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.82
MACD Signal -0.90
20-Day Bollinger Lower Band 21.45
20-Day Bollinger Middle Band 33.04
20-Day Bollinger Upper Band 44.63
Beta 2.00
RSI 36.21
50-Day SMA 64.30
150-Day SMA 107.48
200-Day SMA 141.61

System

Modified 5/13/2025 5:39:20 AM EST